Company Overview and News
The online retail stocks were hit hard on Jun 21, 2018 on the ruling of the supreme court of the United States (SCOTUS) on sales tax. The 5-4 ruling permits states to collect sales taxes from online and out-of-state retailers. The latest decision reverses a 1992 Supreme Court ruling that prohibited the practice.
OSTK CLIX AMZN RTH KSS WMT EBAY
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
The futures traded lower Thursday morning, and while some of the current political turmoil over immigration seems to be relieved, trade worries continue. Once again on Wednesday, the Russell 2000 index, which tracks the smaller capitalization companies, posted another record high. This streak of record highs for the index shows that many investors are moving capital to the companies that have a larger percentage of their sales and services business in the United States — a solid move if the tariff and trade war issues are prolonged.
SIRI GLW CHTR NKE BDX LULU KSS TRI PYPL
Retail stocks have been hot as a pistol of late. Perhaps their demise at the hands of Amazon.com, Inc. (NASDAQ:AMZN) was greatly exaggerated. Or maybe the expectations bar was set so low that upside surprises were all but a guarantee. Regardless of the reason, the retail industry is seeing its constituents pepper the new highs list.
TGT AMZN KSS
Online retail sales continue to soar, with bellwether Amazon.com, Inc.’s (NASDAQ:AMZN) market cap topping $800 billion. But, their outsized gains haven’t hampered traditional retailers much. All of retailers have been part of a broad-based rally so far this year but hardly any of them are trading near peak levels. Obviously, they have more room to run and this growth narrative is well supported by strong fundamentals.
BGFV BURL GES M WFM AMZN LULU AAPL AEO DKS KSS FL URBN
In the value stocks versus growth stocks tug-of-war, growth stocks have been the unequivocal winner for the past several years. But that may change soon.
SIG TIF TWX SKX WMT KR AMZN NKE AAPL DKS KSS KITE INTC DIS GE GEC AMC GILD M TWC FOSL SIG TGT T MU ZUMZ GNE GPS NTAP FL
The futures are trading solidly higher across the board this Thursday morning as the financial world and investors continue to digest yesterday’s commentary from the Federal Reserve. As expected, the Federal Funds rate was increased by 25 basis points or ¼% to 2%, the highest level since 2008, during the financial crisis.
COF.PRG COF.PRH DB UNIT COF.WS TWX MS.PRE COF.PRP MS.PRF MS.PRG MS.PRA HPE WYND COF-D COF-C COF-F AMAT NUS KSS MS COF.PRC COF.PRD COF.PRF TTMI STLD COF-P GSKY XPO KBR COF TWC MS.PRI TEX WRB MS.PRK HMSY ROKU WTI TRI CAKE
For the last five years we were told over and over that Amazon.com (NASDAQ: AMZN) would ultimately change retail as we know it, and the end for brick-and-mortar chains was right around that corner. Guess what? While the Amazon model surely changed the landscape of retail, mostly for the better, and certainly for the future, the predictions of retail doom were overstated.
UA AMZN KORS UAA KSS GPS FL
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to KSS / Kohl's Corp. on message board site Silicon Investor.
|KSS: Kohlu0027s Corporation||Kevin Landis, PEB, KSS, AREM, GCW, Articles|
as of ET